Even with decades of research, treatment for many neurodegenerative diseases remain illusive. From Alzheimer’s to Huntington’s, our collective understanding of these diseases has advanced, but only seen a trickle of clinical trial progress through the drug development pipeline. During this webinar, GNS is joined by Amrita Mohan of CHDI, a biomedical research organization devoted to developing drugs that will slow the progression of Huntington’s disease and provide meaningful clinical benefit to patients as quickly as possible. We discuss how CHDI collaborated to provide insight into the following:

  1. How can we identify markers of patient subpopulations?
  2. Can we accurately discern slow vs. fast-progression patients?
  3. What can we learn about the mechanisms underlying Huntington’s progression?

In this 45-minute webinar, we cover how CHDI and GNS leveraged best-in-class genomic data and computational modeling to predict disease progression.

View content.